See more : Guardian Capital Group Limited (GRCGF) Income Statement Analysis – Financial Results
Complete financial analysis of Pulmatrix, Inc. (PULM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pulmatrix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Spirent Communications plc (SPT.L) Income Statement Analysis – Financial Results
- T-REX Acquisition Corp. (TRXA) Income Statement Analysis – Financial Results
- First National Corporation (FXNC) Income Statement Analysis – Financial Results
- Passus S.A. (PAS.WA) Income Statement Analysis – Financial Results
- Braveheart Resources Inc. (2ZR.F) Income Statement Analysis – Financial Results
Pulmatrix, Inc. (PULM)
About Pulmatrix, Inc.
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.30M | 6.07M | 5.17M | 12.63M | 7.91M | 153.00K | 335.00K | 835.00K | 1.20M | 352.00K | 653.00K | 0.00 |
| Cost of Revenue | 15.52M | 1.55M | 15.38M | 0.00 | 12.85M | 12.97M | 10.24M | 10.15M | 7.19M | 6.59M | 8.56M | 0.00 |
| Gross Profit | -8.22M | 4.53M | -10.21M | 12.63M | -4.94M | -12.81M | -9.91M | -9.32M | -5.99M | -6.24M | -7.91M | 0.00 |
| Gross Profit Ratio | -112.63% | 74.55% | -197.58% | 100.00% | -62.39% | -8,374.51% | -2,957.61% | -1,115.81% | -498.42% | -1,772.16% | -1,211.49% | 0.00% |
| Research & Development | 15.52M | 18.24M | 15.38M | 15.61M | 12.85M | 12.97M | 10.24M | 10.15M | 7.19M | 1.38M | 258.00K | 20.00K |
| General & Administrative | 6.52M | 6.78M | 6.38M | 6.89M | 8.49M | 7.52M | 7.57M | 8.02M | 9.63M | 1.74M | 265.00K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.40M | 0.00 | 0.00 | 0.00 |
| SG&A | 6.52M | 6.78M | 6.38M | 6.89M | 8.49M | 7.52M | 7.57M | 8.02M | 17.03M | 1.74M | 265.00K | 0.00 |
| Other Expenses | 0.00 | -198.00K | -11.00K | -239.00K | -205.00K | 22.00K | 0.00 | 7.53M | 0.00 | 0.00 | 0.00 | 10.00K |
| Operating Expenses | 22.04M | 25.02M | 21.76M | 22.50M | 21.33M | 20.48M | 17.81M | 18.17M | 24.22M | 3.12M | 523.00K | 30.00K |
| Cost & Expenses | 22.04M | 25.02M | 21.76M | 22.50M | 21.33M | 20.48M | 17.81M | 18.17M | 24.22M | 3.12M | 523.00K | 30.00K |
| Interest Income | 867.00K | 309.00K | 7.00K | 82.00K | 301.00K | 27.00K | 0.00 | 0.00 | 17.00K | 17.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 186.00K | 643.00K | 881.00K | 953.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.48M | 1.55M | 1.24M | 1.04M | 765.00K | 231.00K | 246.00K | 250.00K | 232.00K | 2.00K | 352.00K | 0.00 |
| EBITDA | -13.27M | -17.40M | -15.35M | -9.86M | -13.24M | -20.15M | -17.17M | -29.67M | -25.21M | -3.12M | -3.12M | -30.00K |
| EBITDA Ratio | -181.76% | -312.09% | -251.75% | 3.72% | -158.82% | -13,122.88% | -5,142.99% | -2,045.75% | -1,897.25% | -885.23% | -80.09% | 0.00% |
| Operating Income | -14.74M | -18.95M | -20.17M | -573.00K | -20.69M | -20.33M | -17.48M | -24.87M | -23.02M | -3.12M | -523.00K | -30.00K |
| Operating Income Ratio | -201.97% | -312.09% | -390.15% | -4.54% | -261.59% | -13,288.24% | -5,216.42% | -2,977.96% | -1,916.57% | -885.80% | -80.09% | 0.00% |
| Total Other Income/Expenses | 619.00K | 111.00K | -4.00K | -9.45M | 96.00K | -232.00K | -581.00K | -5.94M | -3.15M | -17.44M | 5.32M | 0.00 |
| Income Before Tax | -14.12M | -18.84M | -20.17M | -19.31M | -20.60M | -20.56M | -18.06M | -30.80M | -26.17M | -3.12M | -523.00K | -30.00K |
| Income Before Tax Ratio | -193.49% | -310.26% | -390.23% | -152.83% | -260.38% | -13,439.87% | -5,389.85% | -3,688.86% | -2,178.77% | -885.80% | -80.09% | 0.00% |
| Income Tax Expense | 0.00 | -111.00K | 2.33M | 9.21M | -205.00K | 68.00K | -62.00K | -2.96M | 2.20M | -15.07M | -2.60M | 0.00 |
| Net Income | -14.12M | -18.73M | -22.51M | -28.52M | -20.39M | -20.56M | -18.06M | -27.84M | -26.17M | -3.12M | -523.00K | -30.00K |
| Net Income Ratio | -193.49% | -308.43% | -435.38% | -225.70% | -257.79% | -13,439.87% | -5,389.85% | -3,334.49% | -2,178.77% | -885.80% | -80.09% | 0.00% |
| EPS | -3.87 | -5.43 | -8.31 | -19.83 | -24.37 | -99.67 | -186.42 | -375.87 | -646.91 | -765.72 | -130.75 | -0.18 |
| EPS Diluted | -3.87 | -5.43 | -8.31 | -19.83 | -24.37 | -99.67 | -186.42 | -375.87 | -646.91 | -765.72 | -130.75 | -0.18 |
| Weighted Avg Shares Out | 3.65M | 3.45M | 2.71M | 1.44M | 836.70K | 206.32K | 96.86K | 74.08K | 40.45K | 4.07K | 4.00K | 170.00K |
| Weighted Avg Shares Out (Dil) | 3.65M | 3.45M | 2.71M | 1.44M | 836.70K | 206.32K | 96.86K | 74.08K | 40.45K | 4.07K | 4.00K | 170.00K |
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Which U.S. Companies Are Cutting Ties With Russia? See Latest List.
Pulmatrix (PULM) Stock: 1-For-20 Reverse Split Goes Into Effect
Pulmatrix, Inc. (PULM) Reports Q3 Loss, Misses Revenue Estimates
Bet on Rising P/E Investing With These Top 5 Stocks
Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update
PULM Stock: Over 4% Increase Pre-Market Explanation
Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update
Source: https://incomestatements.info
Category: Stock Reports